Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
China Resources Pharmaceutical Group has launched a public tender to sell about 5.88% of its equity stake in Tianmai Biotechnology Development Co., Ltd. through the Shanghai United Assets and Equity Exchange, with an initial minimum listing price of roughly RMB0.51 billion. The planned sale is independent of a prior Tianmai stake disposal announced in February 2026 and would reduce the group’s current combined 23.75% holding in the biotech firm if completed.
The company has not yet identified a transferee or signed any binding agreements, and the transaction remains contingent on the tender process and execution of definitive contracts. The move signals an ongoing reshaping of China Resources Pharmaceutical’s investment portfolio in biotechnology assets, while the company cautions shareholders and potential investors about the uncertainty and potential impact on its holdings until the process concludes.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company operating through multiple subsidiaries. The group focuses on investment and operations across the pharmaceutical value chain, including drug manufacturing, distribution and related healthcare businesses in mainland China and surrounding markets.
YTD Price Performance: 2.25%
Average Trading Volume: 9,506,755
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.59B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.